We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
14 own
13 watching
Current Price
$8.07
$0.27
(3.46%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
397.03M
52-Week High
37.045
52-Week Low
6.91
Average Volume
0.48M
Dividend Yield
--
P/E Ratio
--
Market Capitalization397.03M
52-Week High37.045
52-Week Low6.91
Average Volume0.48M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
2 months ago
Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? PR Newswire NEW YORK, Oct. 3, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire...
Ticker Report
6 months ago
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased...
Zolmax
6 months ago
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased their price objective on ...
Ticker Report
6 months ago
Northern Trust Corp lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX Get Rating) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 455,411 shares of the company&#...
Zolmax
6 months ago
Northern Trust Corp cut its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX Get Rating) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 455,411 shares of the companys stock after ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$8.07
$0.27
(3.46%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00